BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

Kemas kini terakhir: 12 Mar, 1:26PM

60.07

-1.45 (-2.35%)

  • 1H -2.35%
  • 5H 1.98%
  • 1B -0.19%
  • 6B 12.40%
  • Tahun Ke Tarikh 5.77%
  • 1T 17.54%
  • 5T 3.79%
Penutupan Terdahulu 61.51
Buka 60.72
Jumlah Dagangan 6,594,723
Purata Dagangan (3B) 11,906,520
Modal Pasaran 121,890,496,512
Harga / Pendapatan (P/E Ke hadapan) 8.81
Harga / Jualan (P/S) 2.50
Harga / Buku (P/B) 7.42
Julat 52 Minggu
39.35 (-34%) — 63.33 (5%)
Tarikh Pendapatan 24 Apr 2025
Hasil Dividen (DY TTM) 4.03%
Margin Keuntungan -18.53%
Margin Operasi (TTM) 22.66%
EPS Cair (TTM) -4.41
Pertumbuhan Hasil Suku Tahunan (YOY) 7.50%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -95.90%
Jumlah Hutang/Ekuiti (D/E MRQ) 312.77%
Nisbah Semasa (MRQ) 1.25
Aliran Tunai Operasi (OCF TTM) 15.19 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 16.89 B
Pulangan Atas Aset (ROA TTM) 6.55%
Pulangan Atas Ekuiti (ROE TTM) -38.95%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok Bristol-Myers Squibb Company Menaik Menaik

AISkor Stockmoo

0.8
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga -1.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal 0.5
Purata 0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BMY 122 B 4.03% - 7.42
JNJ 369 B 3.24% 26.47 5.39
ABBV 331 B 3.36% 78.23 99.47
PFE 130 B 7.36% 16.29 1.48
GSK 70 B 4.54% 23.00 4.47
LLY 663 B 0.73% 62.88 52.04

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Value
% Dimiliki oleh Orang Dalam 0.07%
% Dimiliki oleh Institusi 80.57%
81.0081.0072.0072.0063.0063.0054.0054.0045.0045.00Harga Sasaran MedianQ2 '20Q2 '20Q3 '20Q3 '20Q4 '20Q4 '20Q1 '21Q1 '21Q2 '21Q2 '21Q3 '21Q3 '21Q4 '21Q4 '21Q1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25
Julat 52 Minggu
39.35 (-34%) — 63.33 (5%)
Julat Harga Sasaran
55.00 (-8%) — 65.00 (8%)
Tinggi 65.00 (Citigroup, 8.22%) Pegang
65.00 (Truist Securities, 8.22%) Beli
Median 63.50 (5.72%)
Rendah 55.00 (Cantor Fitzgerald, -8.43%) Pegang
Purata 61.75 (2.81%)
Jumlah 1 Beli, 3 Pegang
Harga Purata @ Panggilan 57.89
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Wells Fargo 07 Feb 2025 62.00 (3.22%) Pegang 56.85
Cantor Fitzgerald 04 Feb 2025 55.00 (-8.43%) Pegang 59.12
Citigroup 28 Jan 2025 65.00 (8.22%) Pegang 58.76
Truist Securities 08 Jan 2025 65.00 (8.22%) Beli 56.81

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
28 Mar 2025 Pengumuman Bristol Myers Squibb Receives Positive CHMP Opinion for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo for Resectable Non-Small Cell Lung Cancer in Patients with Tumor Cell PD-L1...
28 Mar 2025 Pengumuman Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
20 Mar 2025 Pengumuman Cardurion Pharmaceuticals Appoints Karen Lewis as Chief People Officer
14 Mar 2025 Pengumuman Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
10 Mar 2025 Pengumuman 2seventy bio Enters into Definitive Agreement to be Acquired by Bristol Myers Squibb
08 Mar 2025 Pengumuman Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
07 Mar 2025 Pengumuman Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
03 Mar 2025 Pengumuman Bristol Myers Squibb Announces Dividend
25 Feb 2025 Pengumuman Bristol Myers Squibb to Participate in Upcoming Investor Conferences
24 Feb 2025 Pengumuman U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Supplemental Biologics License Application for Opdivo® Plus Yervoy® for Patients with Unresectable or Metastatic Microsatellite Instability-High or Mismatch Repair Deficient...
20 Feb 2025 Pengumuman BioArctic's global license agreement with Bristol Myers Squibb for PyroGlutamate-amyloid-beta antibody program effective after antitrust clearance and closing
19 Feb 2025 Pengumuman Bristol Myers Squibb Announces Opdivo® Plus Chemotherapy as the First and Only Neoadjuvant-Only Immuno-Oncology Therapy to Demonstrate Statistically Significant and Clinically Meaningful Overall Survival in Resectable Non-Small Cell Lung Cancer
16 Feb 2025 Pengumuman New Five-Year Sotyktu (deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
13 Feb 2025 Pengumuman Bristol Myers Squibb Provides Update on Phase 3 RELATIVITY-098 Trial
10 Feb 2025 Pengumuman Bristol Myers Squibb Announces Positive Topline Results for Breyanzi® (lisocabtagene maraleucel) in Adult Patients with Relapsed or Refractory Marginal Zone Lymphoma
10 Feb 2025 CNBC Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
06 Feb 2025 Pengumuman Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024
06 Feb 2025 CNBC Bristol Myers Squibb plans $2 billion in cost cuts by 2027, issues weak guidance
31 Jan 2025 Pengumuman Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
31 Jan 2025 Pengumuman Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
25 Jan 2025 Pengumuman Bristol Myers Squibb Presents Results from CheckMate -8HW Analysis Evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) Compared to Opdivo Monotherapy...
17 Jan 2025 CNBC Ozempic is in the next round of Medicare drug price negotiations. See the full list of 15 medications
15 Jan 2025 CNBC Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
13 Jan 2025 Pengumuman ArsenalBio and Bristol Myers Squibb Achieve Milestone for AB-4000 Series as Part of Ongoing Multi-Program Collaboration to Advance Next-Generation T Cell Therapies for Solid Tumors
Papar semua
Hasil Dividen (DY TTM) 4.03%
Purata Hasil Dividen 5T 3.55%
Nisbah Pembayaran 59.84%
Jangkaan Pembayaran Dividen Seterusnya Aug 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
03 Jan 2025 11 Dec 2024 03 Feb 2025 0.62 Tunai
04 Oct 2024 10 Sep 2024 01 Nov 2024 0.6 Tunai
05 Jul 2024 18 Jun 2024 01 Aug 2024 0.6 Tunai
04 Apr 2024 01 Mar 2024 01 May 2024 0.6 Tunai
04 Jan 2024 06 Dec 2023 01 Feb 2024 0.6 Tunai
05 Oct 2023 20 Sep 2023 01 Nov 2023 0.57 Tunai
06 Jul 2023 14 Jun 2023 01 Aug 2023 0.57 Tunai
06 Apr 2023 03 Mar 2023 01 May 2023 0.57 Tunai
05 Jan 2023 08 Dec 2022 01 Feb 2023 0.57 Tunai
06 Oct 2022 14 Sep 2022 01 Nov 2022 0.54 Tunai
30 Jun 2022 15 Jun 2022 01 Aug 2022 0.54 Tunai
31 Mar 2022 01 Mar 2022 02 May 2022 0.54 Tunai
06 Jan 2022 13 Dec 2021 01 Feb 2022 0.54 Tunai
30 Sep 2021 09 Sep 2021 01 Nov 2021 0.49 Tunai
01 Jul 2021 17 Jun 2021 02 Aug 2021 0.49 Tunai
31 Mar 2021 01 Mar 2021 03 May 2021 0.49 Tunai
31 Dec 2020 10 Dec 2020 01 Feb 2021 0.49 Tunai
01 Oct 2020 10 Sep 2020 02 Nov 2020 0.45 Tunai
02 Jul 2020 11 Jun 2020 03 Aug 2020 0.45 Tunai
02 Apr 2020 02 Mar 2020 01 May 2020 0.45 Tunai
02 Jan 2020 06 Dec 2019 03 Feb 2020 0.45 Tunai
03 Oct 2019 12 Sep 2019 01 Nov 2019 0.41 Tunai
03 Jul 2019 14 Jun 2019 01 Aug 2019 0.41 Tunai
04 Apr 2019 08 Mar 2019 01 May 2019 0.41 Tunai
03 Jan 2019 07 Dec 2018 01 Feb 2019 0.41 Tunai
04 Oct 2018 13 Sep 2018 01 Nov 2018 0.4 Tunai
05 Jul 2018 15 Jun 2018 01 Aug 2018 0.4 Tunai
05 Apr 2018 01 Mar 2018 01 May 2018 0.4 Tunai
04 Jan 2018 07 Dec 2017 01 Feb 2018 0.4 Tunai
05 Oct 2017 13 Sep 2017 01 Nov 2017 0.39 Tunai
05 Jul 2017 13 Jun 2017 01 Aug 2017 0.39 Tunai
05 Apr 2017 02 Mar 2017 01 May 2017 0.39 Tunai
04 Jan 2017 08 Dec 2016 01 Feb 2017 0.39 Tunai
05 Oct 2016 03 Aug 2016 01 Nov 2016 0.38 Tunai
29 Jun 2016 07 Jun 2016 01 Aug 2016 0.38 Tunai
30 Mar 2016 03 Mar 2016 02 May 2016 0.38 Tunai
30 Dec 2015 08 Dec 2015 01 Feb 2016 0.38 Tunai
30 Sep 2015 17 Sep 2015 02 Nov 2015 0.37 Tunai
01 Jul 2015 16 Jun 2015 03 Aug 2015 0.37 Tunai
01 Apr 2015 02 Mar 2015 01 May 2015 0.37 Tunai
30 Dec 2014 09 Dec 2014 02 Feb 2015 0.37 Tunai
01 Oct 2014 16 Sep 2014 03 Nov 2014 0.36 Tunai
01 Jul 2014 17 Jun 2014 01 Aug 2014 0.36 Tunai
02 Apr 2014 03 Mar 2014 01 May 2014 0.36 Tunai
31 Dec 2013 19 Dec 2013 03 Feb 2014 0.36 Tunai
02 Oct 2013 17 Sep 2013 01 Nov 2013 0.35 Tunai
02 Jul 2013 19 Jun 2013 01 Aug 2013 0.35 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 0.620 1 1.03
2024 2.40 4 4.24
2023 2.28 4 4.44
2022 2.16 4 3.00
2021 1.96 4 3.14
2020 1.80 4 2.90
2019 1.64 4 2.56
2018 1.60 4 3.08
2017 1.56 4 2.55
2016 1.52 4 2.60
2015 1.48 4 2.15
2014 1.44 4 2.44
2013 0.700 2 1.32
Papar semua
61.9861.9860.6260.6259.2559.2557.8957.8956.5356.53Mar 25Mar 25Mar 26Mar 26Mar 27Mar 27Mar 28Mar 28Mar 31Mar 31Apr 1Apr 1Apr 2Apr 2Apr 3Apr 3

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
0.8000.8000.6000.6000.4000.4000.2000.2000.0000.000MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda